

Metastatic Breast Cancer: Individualizing Treatment

How to Receive CE Credit

To earn free CE credit for watching this program, you must complete this test online.

Go to www.discoveryhealthCME.com and follow the instructions to complete the post-test and evaluation online. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and you will be able to print the appropriate credit certificate right from your computer.

CE Test Questions

1. True or false: A premenopausal woman with hormone receptor-positive metastatic breast cancer will need to undergo ablation or suppression of ovarian function prior to receiving an aromatase inhibitor.
2. True or false: Combination chemotherapy is an appropriate treatment option for most women with hormone receptor-positive metastatic breast cancer who experience disease progression on initial endocrine therapy.
3. True or false: Combination chemotherapy has been shown to increase overall survival in women with metastatic breast cancer when compared with sequential single-agent chemotherapy.
4. True or false: According to the National Comprehensive Cancer Network (NCCN) guidelines, lapatinib is the only HER2-directed agent appropriate for a woman with HER2-positive metastatic breast cancer who experiences disease progression on a trastuzumab-containing regimen.
5. True or false: Bisphosphonates have been shown to decrease skeletal morbidity and bone pain in women with breast cancer that has metastasized to the bone.

CE Evaluation

Metastatic Breast Cancer: Individualizing Treatment

1. The program content helped me to achieve the following objectives:

Identify first-line and subsequent line endocrine therapy options for patients with hormone receptor positive cancer

Strongly Agree Agree Undecided Disagree Strongly Disagree

Identify treatment approaches for trastuzumab-exposed patients

Strongly Agree Agree Undecided Disagree Strongly Disagree

Describe single-agent and combination therapies, including biologic agents, being evaluated in clinical trials

Strongly Agree Agree Undecided Disagree Strongly Disagree

Counsel patients about some of the risks and benefits of therapeutic options

Strongly Agree Agree Undecided Disagree Strongly Disagree

Describe the appropriate use of supportive care options

Strongly Agree Agree Undecided Disagree Strongly Disagree

2. Time spent completing this activity?

< 30 min 30 min 45 min 1 hr 1.5 hrs .>1.5 hrs

Rate the extent to which you agree or disagree:

3. I was satisfied with the overall quality of this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

4. This activity addressed issues that will help me improve my professional competence and/or performance.

Strongly Agree Agree Undecided Disagree Strongly Disagree

5. You will make a change in your practice as a result of participation in this activity.

Strongly Agree Agree Undecided Disagree Strongly Disagree

6. The activity presented scientifically rigorous, unbiased, and balanced information.

Strongly Agree Agree Undecided Disagree Strongly Disagree

7. Individual presentations were free of commercial bias.

Strongly Agree Agree Undecided Disagree Strongly Disagree

8. Information presented in this activity is applicable to my professional role.

Strongly Agree Agree Undecided Disagree Strongly Disagree

9. Which ONE of the following best describes the impact of this activity on you:

- a. I plan to incorporate these updates in cancer management into my practice.
- b. I do not plan to incorporate these updates in cancer management into my practice.
- c. Not applicable to my healthcare role.

10. For Question #9, if you selected "B" please list any factors that may be acting as barriers to implementing change.

11. If commercial bias was noted, please explain.

12. To improve your professional competence or performance, on what oncology topics would you like future NCCN education programs to be focused?

13. I am printing the following certificate:

- a. MD
- b. Non-MD
- c. Nurse

14. Additional Feedback.